logo-loader
Outlook Therapeutics

Outlook Therapeutics over 50% enrolled in clinical study to treat wet AMD

Outlook Therapeutics (NASDAQ:OTLK) CEO Larry Kenyon sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Quick facts: Outlook Therapeutics

Price: $1.90

Market: NASDAQ
Market Cap: $53.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Fireweed Zinc releases details of drill holes at Tom North...

Fireweed Zinc (CVE: FWZ) CEO Brandon MacDonald sat down with Steve Darling from Proactive Vancouver to discuss their latest result from drilling on the Macmillan Pass Project in the Yukon.  MacDonald telling Proactive the results they found and why they decided to do a step out hole as...

28 minutes ago

2 min read